Shots:
- The Chinese NMPA has approved the initiation of P-II trials of AK139 across seven indications, incl. COPD, severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, CRSwNP, mod. to sev. atopic dermatitis, & prurigo nodularis
- AK139 is an IL-4Rα/ST2 bispecific antibody that blocks both the IL-4/IL-13 pathway via binding to IL-4Rα subunit & the IL-33/ST2 inflammatory pathway
- Early data show AK139 has strong bispecific binding & favorable in vitro and in vivo activity, delivering superior inhibition of inflammatory cytokines & reduced tissue inflammatory cell infiltration compared with single-target IL-4 or ST2 antibodies
Ref: PRnewswire | Image: Akeso | Press Release
Related News: Akeso’s Ivonescimab + CT Receives the NMPA Breakthrough Therapy Designation for Biliary Tract Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
